GW Pharmaceuticals PLC announced positive results from its latest phase II study on non-smoked, cannabis related prescription-based medicines, following a 34 patient study in patients with Multiple Sclerosis, Spinal Cord Injury and other conditions causing severe pain.
GW Pharma said the results demonstrate 'significant benefits for patients', notably in the relief of pain and improvement in sleep.
The data was presented at the American Academy of Pain Management in Reno, Nevada by Dr Willy Notcutt on Saturday.
"The data shows improvements with all three of our cannabis-based medicines and we therefore believe that there will be a market for all three medicines in pain treatment in due course," executive chairman Dr Geoffrey Guy said.
At the same time, he said that patient recruitment and data analysis
for a number of Phase III trials is ahead of schedule and he now expects
to announce preliminary Phase III results in November.
© AFX News